Tu Ting-Hao, Lu Jeng-Wei, Ho Yi-Jung, Lui Shan-Wen, Hsieh Ting-Yu, Wang Kuang-Yih, Liu Feng-Cheng
Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Department of Bioscience and Biotechnology, National Taiwan Ocean University, Keelung, Taiwan, R.O.C.
In Vivo. 2025 Sep-Oct;39(5):3014-3024. doi: 10.21873/invivo.14103.
BACKGROUND/AIM: Pericarditis is a common cardiovascular complication associated with systemic lupus erythematosus (SLE). Oxidative stress plays a significant role in disease pathology. Molecular hydrogen has emerged as a promising therapeutic option with its antioxidant, anti-inflammatory, and antiapoptotic properties. While prior studies have demonstrated its cardioprotective effects, research on its immunomodulatory potential in autoimmune diseases remains limited; therefore, this article presents a case study with SLE experiencing pericarditis and pleuritis, receiving hydrogen therapy in October 2024 as part of an effort to evaluate its potential in modulating immune responses and alleviating disease symptoms.
This is the case of a 49-year-old Taiwanese female diagnosed with SLE, alongside pericarditis, pleuritis, and multi-organ impairments. Despite initial treatment and intermittent follow-ups, the patient experienced recurrent disease exacerbations, which was managed with immunomodulatory therapies. In October 2024, molecular hydrogen supplementation was introduced as an adjuvant therapy. Immunophenotypic analysis revealed dynamic changes in the percentages of immune cells, with decreasing trend of Tr1 cells and increasing trend of naïve Treg cells, B cell subsets expressing Fas, and transitional B cells following molecular hydrogen therapy.
Molecular hydrogen therapy had potential to modulate immune markers in this case study. Further investigation into its clinical efficacy and safety is necessary for the development of treatment guidelines.
背景/目的：心包炎是系统性红斑狼疮（SLE）常见的心血管并发症。氧化应激在疾病病理过程中起重要作用。氢气因其抗氧化、抗炎和抗凋亡特性，已成为一种有前景的治疗选择。虽然先前的研究已证明其心脏保护作用，但关于其在自身免疫性疾病中的免疫调节潜力的研究仍然有限；因此，本文介绍了一例患有心包炎和胸膜炎的SLE患者的病例研究，该患者于2024年10月接受氢气治疗，作为评估其调节免疫反应和缓解疾病症状潜力的一部分。
这是一名49岁的台湾女性患者，被诊断为SLE，伴有心包炎、胸膜炎和多器官损害。尽管进行了初始治疗和间歇性随访，但患者疾病仍反复发作，通过免疫调节疗法进行管理。2024年10月，引入氢气补充作为辅助治疗。免疫表型分析显示免疫细胞百分比发生动态变化，氢气治疗后Tr1细胞百分比呈下降趋势，幼稚Treg细胞、表达Fas的B细胞亚群和过渡性B细胞百分比呈上升趋势。
在本病例研究中，氢气治疗具有调节免疫标志物的潜力。为制定治疗指南，有必要进一步研究其临床疗效和安全性。
